QuidelOrtho (NASDAQ:QDEL) Trading Up 6.4% – Time to Buy?

QuidelOrtho Corporation (NASDAQ:QDEL) shares were up 6.4% during mid-day trading on Tuesday . The stock traded as high as $11.36 and last traded at $11.53. Approximately 1,083,027 shares changed hands during trading, a decline of 42% from the average daily volume of 1,858,379 shares. The stock had previously closed at $10.84.

Analyst Upgrades and Downgrades

QDEL has been the topic of a number of recent analyst reports. UBS Group reissued a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Jefferies Financial Group cut shares of QuidelOrtho from a “buy” rating to a “hold” rating and decreased their price target for the company from $35.00 to $12.50 in a report on Thursday, May 7th. Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Zacks Research downgraded shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $14.88.

QuidelOrtho Trading Up 6.1%

The stock has a market cap of $784.40 million, a P/E ratio of -0.64 and a beta of 0.75. The business’s 50 day simple moving average is $14.55 and its 200 day simple moving average is $22.65. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The company had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. During the same quarter last year, the business earned $0.74 EPS. QuidelOrtho’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, analysts expect that QuidelOrtho Corporation will post 1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On QuidelOrtho

Hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC boosted its position in QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after buying an additional 886 shares in the last quarter. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $29,000. Hantz Financial Services Inc. raised its stake in shares of QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after acquiring an additional 362 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of QuidelOrtho by 118.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the company’s stock worth $38,000 after acquiring an additional 693 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of QuidelOrtho by 322.2% in the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after acquiring an additional 1,015 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.